Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Soon

<< Previous

Bullboard Posts

Next >>

Comment by AngelaLon Jan 31, 2021 3:34am

169 Views

Post# 32430586

RE:RE:RE:RE:RE:RE:RE:Soon

Both Novavax and J&J reported disappointing results from their vaccine trials. In the case of Novavax, they only showed 60% efficacy in their South African trial due to the poor performance against the mutant strain that is prevalent there (and has now spread globally). J&J did even worse, showing 65% protection against the non-mutant strains. Bottom line, not one of the vaccines available today is highly protective against the mutant strains. And new mutant strains are appearing weekly! I have high hopes that R-107 can fill the gap. Kalytera looks set to hit it out of the park given its positioning as the only nitric oxide therapy that can treat COVID throughout the whole body.

<< Previous

Bullboard Posts

Next >>

High-grade gold potential in the world’s best mining jurisdiction